Press Releases

Company executives, scientists and government officials will bring a global perspective as featured presenters at BIO’s 9th annual World Congress on Biotechnology and Bioprocessing. 

Feb 15 2012

The bill will modernize the FDA and accelerate patient access to cures and new treatments.

“The biotechnology industry has long been an engine for economic development and job creation across the country and our sector is working to add more high-wage high-skilled jobs to our workforce." 

“We are excited to bring this conference to Orlando to highlight the industry's growth, the importance of this industrial and environmental biotechnology for generating green jobs, making greener products and cleaner processes all aimed at building a biobased economy." 

BIO President and CEO Jim Greenwood issued the following statement regarding the newly released U.S. Food and Drug Administration (FDA) guidance for the review and approval of biosimilars.

Because of their tremendous environmental and economic benefits, farmers around the world continue to adopt genetically engineered (GE) crops according to a report released today by the International Service for the Acquisition of Agri-Biotech Applications (ISAAA). 

Feb 1 2012

In the testimony, Richard Pops, Alkermes plc Chairman and CEO,  stressed the need for a quick reauthorization of the Prescription Drug User Fee Act (PDUFA) and enactment of the enhancements recommended in the PDUFA V agreement. 

Jan 31 2012

The Biotechnology Industry Organization (BIO) announces plenary sessions, Business Roundtables and Therapeutic Workshops selected for the 14th Annual BIO CEO & Investor Conference.

The USDA's loan guarantee program is helping advanced biofuel companies attract necessary financing for commercial projects. Projects like ZeaChem's can bring jobs and economic growth to rural areas.

BIO calls on the administration and Congress to embrace proposals to Unleash the Promise of Biotechnology.

The 2012 BIO International Convention will feature a program packed with more than 125 breakout sessions.

Biotech company Novozymes provides technology necessary for progress in commercializing advanced biofuels. 

Fireside Chats to focus on biopharma R&D and corporate strategy.

Bittenbender will spearhead BIO’s engagement in and support of state-level legislative and regulatory issues while promoting the responsible development of the bioscience industry and better understanding of policy issues critical to the industry.

BIO strongly supports the PDUFA V recommendations as they will enhance the drug development and review process through increased transparency and scientific dialogue, advance regulatory science, and strengthen post-market surveillance. 

Biotechnology Industry Organization (BIO) announces programming for 2012 event, to be held in Osaka, Japan.

Dec 19 2011

Extension of cellulosic biofuel tax credits now and eligibility for algae biofuels are needed to help companies raise financing for first-of-a-kind biorefineries.  

Dec 16 2011

Grants will provide critical funding to small emerging biotechnology companies working on promising innovations for treating and curing cancer, diabetes, and HIV/AIDS, among other diseases

Dec 15 2011

FDA:  GE salmon will not have significant impact on the environment

Washington, D.C. (December 15, 2011) – The Senate Commerce, Science, and Transportation Committee’s Subcommitteeon Oceans, Atmosphere, Fisheries, and Coast Guard held a hearing today to examine the environmental issues around genetically engineered (GE) fish.  

Dec 15 2011

Biotechnology companies researching and developing advanced biofuels can help diversify the military’s energy supply and advance U.S. national and energy security objectives.

Dec 14 2011

BIO submitted written testimony to the Senate Finance Subcommittee on Energy, Natural Resources and Infrastructure. In the testimony, BIO noted that sustained, long-term tax policy is vital to emerging alternative energy technologies.

Dec 13 2011

Small Business Innovation Research (SBIR) grants provide critical funding for the development of innovative medical therapies for Cancer, Diabetes and HIV.

Dec 6 2011

Washington, DC (December 6, 2011) – The Biotechnology Industry Organization (BIO) announces program topics planned for the BIO CEO & Investor Conference to be held February 13-14, 2012 at the Waldorf=Astoria in New York City, NY.